Who Exports Flucloxacillin from India — 123 Suppliers Behind a $38.8M Market
India's flucloxacillin export market is supplied by 123 active exporters who collectively shipped $38.8M across 1,146 shipments. MEDREICH LIMITED leads with a 50.6% market share, followed by MICRO LABS LIMITED and KROSYL PHARMACEUTICALS PRIVATE LIMITED. The top 5 suppliers together control 75.5% of total export value, reflecting a concentrated market structure.
Top Flucloxacillin Exporters from India — Ranked by Export Value
MEDREICH LIMITED is the leading flucloxacillin exporter from India, holding a 50.6% share of the $38.8M market across 1,146 shipments from 123 exporters. The top 5 suppliers — MEDREICH LIMITED, MICRO LABS LIMITED, KROSYL PHARMACEUTICALS PRIVATE LIMITED, MILAN LABORATORIES (INDIA) PRIVATE LIMITED, AUROBINDO PHARMA LTD — collectively control 75.5% of total export value, indicating a highly concentrated market. Individual shares are: MEDREICH LIMITED (50.6%), MICRO LABS LIMITED (11.5%), KROSYL PHARMACEUTICALS PRIVATE LIMITED (4.7%), MILAN LABORATORIES (INDIA) PRIVATE LIMITED (4.4%), AUROBINDO PHARMA LTD (4.4%).
Top Flucloxacillin Exporters from India
Ranked by export value · 123 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | MEDREICH LIMITED FLUCLOXACILLIN 500MG CAPSULES BP 2X14SFLUCLOXACILLIN CAPSULES 500MG (STAPHLEXFLUCLOXACILLIN 500MG CAPSULES, HARD | $19.6M | 8 | 50.6% |
| 2 | MICRO LABS LIMITED FLUCLOXACILLIN 500MG CAPSULES BP 2X14SFLUCLOXACILLIN 500MG CAPSULES, HARDFLUCLOXACILLIN 500MG CAPSULES BP 2X14 | $4.4M | 2 | 11.5% |
| 3 | KROSYL PHARMACEUTICALS PRIVATE LIMITED FLUCLOCEN - 250 FLUCLOXACILLIN ORAL SOLUPHARMACEUTICAL PRODUCTS MEDICINES - FLUCLOXATRUST CAPSFLUCLOX 500 - CAMEROON | $1.8M | 1 | 4.7% |
| 4 | MILAN LABORATORIES (INDIA) PRIVATE LIMITED FLUCLOXACILLIN 500MG CAPSULES BP 2X14SFLUCLOXACILLIN 500MG CAPSULES, HARDFLUCLOXACILLIN 500MG CAPSULES BP 2X14 | $1.7M | 3 | 4.4% |
| 5 | AUROBINDO PHARMA LTD FLUCLOXACILLIN SODIUM TABLETS 1000MG(FLUFLUCLOXACILLIN SODIUM TABLETS 1000MG21'SFLUCLOXACILLIN SODIUM TABLETS 1000MG30'S | $1.7M | 1 | 4.4% |
| 6 | KOPRAN LIMITED MACROPEN 500 - TAX INV NO: 711204559 DT: 08.02.2024NOSMACROPEN 500 -TAX INVOICE NO: 711205473 DT: 29.03.2025 | $1.3M | 2 | 3.4% |
| 7 | AJANTA PHARMA LIMITED FLUKOCIN 250 (FLUCLOXACILLIN ORAL SOLUTIFLUKOCIN 500 (FLUCLOXACILLIN CAPSULES 50OXICLAR PFOS 250MG/5ML [FLUCLOXACILLIN O | $860.1K | 5 | 2.2% |
| 8 | MERIT ORGANICS LIMITED | $755.8K | 1 | 1.9% |
| 9 | AUROBINDO PHARMA LIMITED FLUCLOXACILLIN SODIUM TABLETS 1000MG(FLUFLUCLOXACILLIN SODIUM TABLETS 1000MG21'SFLUCLOXACILLIN SODIUM TABLETS 1000MG30'S | $639.9K | 1 | 1.6% |
| 10 | MEDOPHARM PRIVATE LIMITED FLUCLOXACILLIN 500MG CAPSULES BP 2X14SFLUCLOXACILLIN 500MG CAPSULES, HARDFLUCLOXACILLIN 500MG CAPSULES BP 2X14 | $499.9K | 5 | 1.3% |
| 11 | SAKAR HEALTHCARE LIMITED FLUCLOCEN - 250 FLUCLOXACILLIN ORAL SOLUAMOXICILLIN AND FLUCLOXACILLIN CAPSULESAMOXICILLIN AND FLUCLOXACILLIN CAPSULE 2 | $447.2K | 5 | 1.2% |
| 12 | MILAN LABORATORIES INDIA PRIVATE LIMITED FLUCLOXACILLIN 500MG CAPSULES BP 2X14SFLUCLOXACILLIN 500MG CAPSULES, HARDFLUCLOXACILLIN 500MG CAPSULES BP 2X14 | $436.1K | 2 | 1.1% |
| 13 | SCOTT EDIL PHARMACIA LIMITED AMOXICILLIN AND FLUCLOXACILLIN CAPSULESAMOXICILLIN AND FLUCLOXACILLIN CAPSULE 2AMOXICILLIN AND FLUCLOXACILLIN CAPSULES500MGNOS | $320.4K | 9 | 0.8% |
| 14 | MAXHEAL PHARMACEUTICALS (INDIA) LIMITED | $314.5K | 2 | 0.8% |
| 15 | BIOMATRIX HEALTHCARE PRIVATE LIMITED | $278.0K | 5 | 0.7% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Flucloxacillin exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| MEDREICH LIMITED | Not Listed | Yes | No | Not verified | WHO-GMP certified; no FDA listing or warning letters found. |
| MICRO LABS LIMITED | Not Listed | Yes | No | Not verified | WHO-GMP certified; no FDA listing or warning letters found. |
| MILAN LABORATORIES (INDIA) PRIVATE LIMITED | Not Listed | Yes | No | Not verified | WHO-GMP certified; no FDA listing or warning letters found. |
| AUROBINDO PHARMA LTD | Approved | Yes | Yes | Multiple | FDA-approved with multiple ANDAs; WHO-GMP and EU GMP certified. |
| KOPRAN LIMITED | Not Listed | Yes | No | Not verified | WHO-GMP certified; no FDA listing or warning letters found. |
| AJANTA PHARMA LIMITED | Approved | Yes | Yes | Multiple | FDA-approved with multiple ANDAs; WHO-GMP and EU GMP certified. |
| MERIT ORGANICS LIMITED | Not Listed | Yes | No | Not verified | WHO-GMP certified; no FDA listing or warning letters found. |
| MEDOPHARM PRIVATE LIMITED | Not Listed | Yes | No | Not verified | WHO-GMP certified; no FDA listing or warning letters found. |
| SCOTT EDIL PHARMACIA LIMITED | Not Listed | Yes | No | Not verified | WHO-GMP certified; no FDA listing or warning letters found. |
| BIOMATRIX HEALTHCARE PRIVATE LIMITED | Not Listed | Yes | Yes | Not verified | WHO-GMP and EU GMP certified; no FDA listing or warning letters found. |
TransData Nexus reviewed the regulatory standing of 10 leading Flucloxacillin exporters from India. 2 hold US FDA facility approvals, 10 maintain WHO-GMP certification, and 3 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Flucloxacillin sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a pivotal hub for pharmaceutical manufacturing. The city hosts Genome Valley, India's first biotech cluster, and is home to over 800 pharmaceutical companies, including major players like Dr. Reddy’s Laboratories and Aurobindo Pharma. This concentration fosters a robust environment for the production of Active Pharmaceutical Ingredients (APIs) and bulk drugs, essential for antibiotics like Flucloxacillin.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its pharmaceutical formulations. Gujarat contributes nearly 28% of India's pharmaceutical production, with companies such as Zydus Cadila and Torrent Pharmaceuticals headquartered here. The region's advanced infrastructure and regulatory support make it a strategic location for the development and export of finished pharmaceutical products, including Flucloxacillin formulations.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a critical export gateway for India's pharmaceutical industry. Mumbai, being a major port city, facilitates efficient international shipping. The region hosts numerous pharmaceutical companies, leveraging its logistical advantages to distribute products like Flucloxacillin to global markets.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing zone, partly due to favorable tax incentives. Baddi alone houses over 1,000 pharmaceutical units, making it one of Asia's largest pharmaceutical hubs. This region's growth has been instrumental in bolstering India's capacity to produce and export antibiotics such as Flucloxacillin.
5Sourcing Recommendations
- Diversify Supplier Base: While MEDREICH LIMITED dominates Flucloxacillin exports, consider engaging with other top exporters like MICRO LABS LIMITED and KROSYL PHARMACEUTICALS PRIVATE LIMITED to mitigate supply chain risks.
- Leverage Regional Strengths: Utilize Hyderabad for API sourcing, Ahmedabad-Vadodara for formulations, and Mumbai-Thane-Raigad for export logistics to optimize the supply chain.
- Monitor Regulatory Compliance: Ensure suppliers adhere to international quality standards and regulatory requirements to maintain product integrity and market access.
- Assess Infrastructure and Incentives: Evaluate the benefits of manufacturing in regions like Baddi-Nalagarh, considering tax incentives and production capacities to enhance cost-effectiveness.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Flucloxacillin exporters from India
Aurobindo Pharma Ltd — Aurobindo acquires Khandelwal Labs' non-oncology generics business
Aurobindo Pharma Ltd acquired the non-oncology branded generics business of Khandelwal Laboratories Pvt Ltd, enhancing its domestic formulation portfolio in India. - IMPACT: This acquisition is expected to strengthen Aurobindo's position in the domestic market, potentially influencing its export strategies, including Flucloxacillin.
Impact: This acquisition is expected to strengthen Aurobindo's position in the domestic market, potentially influencing its export strategies, including Flucloxacillin.
Aurobindo Pharma Ltd — Aurobindo Pharma acquires remaining stake in GLS Pharma
Aurobindo Pharma Ltd completed the acquisition of the remaining 49% stake in GLS Pharma, gaining full ownership of the oncology-focused company. - IMPACT: Full ownership of GLS Pharma may enhance Aurobindo's oncology portfolio, potentially affecting its resource allocation and focus on other products, including Flucloxacillin.
Impact: Full ownership of GLS Pharma may enhance Aurobindo's oncology portfolio, potentially affecting its resource allocation and focus on other products, including Flucloxacillin.
Aurobindo Pharma Ltd — Aurobindo acquires Veritaz Healthcare's domestic formulations business
Aurobindo Pharma Ltd acquired the domestic formulations business of Veritaz Healthcare Ltd on a slump sale basis for ₹1,710 million, expanding its presence in the Indian pharmaceutical market. - IMPACT: This acquisition strengthens Aurobindo's domestic market presence, which may influence its export dynamics, including Flucloxacillin.
Impact: This acquisition strengthens Aurobindo's domestic market presence, which may influence its export dynamics, including Flucloxacillin.
Common Questions — Flucloxacillin Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which flucloxacillin supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, MEDREICH LIMITED leads with 337 recorded shipments worth $19.6M. MICRO LABS LIMITED (81 shipments) and KROSYL PHARMACEUTICALS PRIVATE LIMITED (3 shipments) are also established high-volume exporters.
Q How many flucloxacillin manufacturers are there in India?
India has 123 active flucloxacillin exporters with a combined export market of $38.8M across 1,146 shipments to 44 countries. The top 5 suppliers hold 75.5% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for flucloxacillin from India?
Average FOB unit price: $11.71 per unit, ranging from $0.02 to $2683.28. Average shipment value: $33.8K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 123 verified Indian exporters of Flucloxacillin ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 1,146 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 44 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1,146 Verified Shipments
123 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists